Cyclin B2 (CCNB2) Stimulates the Proliferation of Triple-Negative Breast Cancer (TNBC) Cells In Vitro and In Vivo

Abstract

Triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer. Currently, targeting therapy makes great advances for the treatment of TNBC, whereas more effective therapeutic targets are urgently needed. Cyclin B2 (CCNB2), which belongs to B-type cyclins, is known as a cell cycle regulator. CCNB2 is synthesized at G1 phase in cancer cells and downregulated at anaphase. The defects of CCNB2 led to the abnormal cell cycle and tumorigenesis. Though there are wide effects of CCNB2 on multiple types of tumors, the potential role of CCNB2 in TNBC progression is still unclear. Herein, we found that CCNB2 was highly expressed in human TNBC tissues and correlated with the prognosis and clinical pathological features including tumor size ( p = 0.022 ∗ ) and pTNM stage ( p = 0.021 ∗ ) of patients with TNBC. CCNB2 could promote the proliferation of TNBC cells in vitro and in mice. Our findings therefore confirmed the involvement of CCNB2 in TNBC progression and provided the evidence that CCNB2 could serve as a promising molecular target of TNBC.

Identification of prognostic biomarkers for suppressing tumorigenesis and metastasis of Hepatocellular carcinoma through transcriptome analysis

“…CCNB2 also found to promote cell cycle progression resulting in tumorigenesis in case of triple negative breast cancer (Wu et al, 2021). It was also identified in the cell cycle progression leading to poor prognosis of HCC (Liu et al, 2020).…”

An integrated analysis of prognostic and immune infiltrates for hub genes as potential survival indicators in patients with lung adenocarcinoma

“…CCNB2 (cyclin B2) is a member of the B-type cyclins family that can interact with p34cdc2, and is a critical component of the cell cycle regulation [ 48 ]. CCNB2 has been shown to promote the proliferation of triple-negative breast cancer cells in vitro and in vivo [ 49 ]. As validated by a comprehensive bioinformatics study, CCNB2 has been identified as a promising therapeutic target for ovarian cancer [ 50 ].…”

Identification of Pathologic and Prognostic Genes in Prostate Cancer Based on Database Mining

“…It was proved that the knockdown of circ_ CCNB2 increased the radiosensitivity of PCa through repressing autophagy by the miR-30b-5p/KIF18A axis, but no biological function of CCNB2 in prostate cancer has been found ( Cai F. et al, 2020 ). CCNB2 was highly expressed in human triple-negative breast cancer (TNBC) tissues and correlated with the prognosis and clinical pathological features ( Wu et al, 2021 ). However, the key targets of CCNB2 in TNBC and its biological functions remain to be found.…”